Centessa Pharmaceuticals plc
CNTA
$29.07
$0.561.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 15.00M | 15.00M | -- | 6.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | 15.00M | 15.00M | -- | 6.85M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.00M | 15.00M | 15.00M | -- | 6.85M |
| SG&A Expenses | 50.18M | 50.45M | 49.71M | 50.81M | 49.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.80M | 221.42M | 210.74M | 201.06M | 168.51M |
| Operating Income | -213.80M | -206.42M | -195.74M | -201.06M | -161.65M |
| Income Before Tax | -239.31M | -226.54M | -220.09M | -232.91M | -158.33M |
| Income Tax Expenses | 3.39M | 3.83M | 3.76M | 2.84M | 2.94M |
| Earnings from Continuing Operations | -242.70 | -230.37 | -223.85 | -235.76 | -161.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -242.70M | -230.37M | -223.85M | -235.76M | -161.27M |
| EBIT | -213.80M | -206.42M | -195.74M | -201.06M | -161.65M |
| EBITDA | -213.03M | -205.65M | -194.96M | -200.25M | -160.84M |
| EPS Basic | -1.83 | -1.78 | -1.81 | -1.99 | -1.52 |
| Normalized Basic EPS | -0.96 | -0.94 | -0.95 | -1.06 | -0.92 |
| EPS Diluted | -1.83 | -1.78 | -1.81 | -1.99 | -1.52 |
| Normalized Diluted EPS | -0.96 | -0.94 | -0.95 | -1.06 | -0.92 |
| Average Basic Shares Outstanding | 532.92M | 515.02M | 490.83M | 457.68M | 423.55M |
| Average Diluted Shares Outstanding | 532.92M | 515.02M | 490.83M | 457.68M | 423.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |